BioXcel Therapeutics Inc
F:BX2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (53.9), the stock would be worth €3.64 (42% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 37.9 | €2.56 |
0%
|
| 3-Year Average | 53.9 | €3.64 |
+42%
|
| 5-Year Average | 55 | €3.72 |
+45%
|
| Industry Average | 6.7 | €0.45 |
-82%
|
| Country Average | 2.4 | €0.16 |
-94%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€25.5m
|
/ |
Jan 2026
$642k
|
= |
|
|
€25.5m
|
/ |
Dec 2026
$1.9m
|
= |
|
|
€25.5m
|
/ |
Dec 2027
$19.3m
|
= |
|
|
€25.5m
|
/ |
Dec 2028
$50.1m
|
= |
|
|
€25.5m
|
/ |
Dec 2029
$182.4m
|
= |
|
|
€25.5m
|
/ |
Dec 2030
$407.4m
|
= |
|
|
€25.5m
|
/ |
Dec 2031
$603.3m
|
= |
|
|
€25.5m
|
/ |
Dec 2032
$736.3m
|
= |
|
|
€25.5m
|
/ |
Dec 2033
$880.3m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
BioXcel Therapeutics Inc
F:BX2
|
29.5m EUR | 37.9 | -0.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 5.7 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 5 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.4 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 9 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 2.7 | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
BioXcel Therapeutics Inc
Glance View
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 89 full-time employees. The company went IPO on 2018-03-08. The company is focused on utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Its two advanced clinical development programs are BXCL501, which is an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is an investigational orally administered systemic innate immune activator for the treatment of castration resistant prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.
